Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/9184
Type: Artigo de periódico
Title: Hiperplasia congênita das supra-renais por deficiência da 21- hidroxilase: altura final de 27 pacientes com a forma clássica
Title Alternative: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: final Height in 27 patients with the classical form
Author: Lemos-Marini, Sofia H.V.
Guerra-Júnior, Gil
Morcillo, André M.
Baptista, Maria Tereza M.
Silva, Luciana O.
Maciel-Guerra, Andréa T.
Abstract: OBJECTIVE: To determine final height (FH) in congenital adrenal hyperplasia (CAH) patients and investigate conditions allowing better height outcome. METHODOLOGY: 13 salt-wasting (SW) and 14 simple virilizing (SV) patients were studied. FH and target height (TH) were transformed into standard deviation score (z). Data were analyzed according to sex, clinical form, age at treatment onset and length of treatment before attaining FH. RESULTS: zFH (n= 27) was -1.57 &plusmn; 1.01. FH (-1.50 &plusmn; 1.03) was below TH (-0.78 &plusmn; 0.84) (n= 25, p< 0.001). FH has not differed according to sex, clinical form and age at therapy onset although there was a trend towards better FH in SW patients and in early treated cases; there was significant difference (p= 0.018) between patients treated for less than 5 years (-2.49 &plusmn; 1.03) and those accompanied longer than 10 years (-1.21 &plusmn; 0.88) before attaining FH. CONCLUSIONS: There was a FH impairment and adult height improvement seems to depend mainly on early diagnosis and treatment.
OBJETIVO: Determinar a altura final (AF) de pacientes com hiperplasia supra-renal congênita e investigar fatores de melhor prognóstico de altura. METODOLOGIA: Estudamos 13 pacientes perdedores de sal (PS) e 14 virilizantes simples (VS). AF e altura-alvo (AA) foram transformadas em escores z. Os dados foram analisados de acordo com sexo, variante clínica, idade do início do tratamento e duração do tratamento até AF. RESULTADOS: O zAF (n= 27) foi -1,57 &plusmn; 1,01. Houve diferença entre AF (-1,50 &plusmn; 1,03) e AA (-0,78 &plusmn; 0,84) (n= 25, p< 0,001). Não houve diferença quanto a sexo, variante e início do tratamento, embora PS e pacientes com terapia precoce tivessem tendência a melhor AF; houve diferença (p= 0,018) entre a estatura de pacientes que atingiram a AF com menos de 5 anos de tratamento (-2,49 &plusmn; 1,03) em relação àqueles tratados por mais de 10 anos (-1,21 &plusmn; 0,88). CONCLUSÃO: Houve comprometimento na AF, e melhor prognóstico parece depender principalmente de diagnóstico e tratamento precoces.
Subject: Estatura
Crescimento
Esteróide 21-hidroxilase
Hiperplasia supra-renal, Congênita
Glândulas supra-renais
Height
Growth
Steroid 21-hydroxylase
Adrenal hyperplasia, Congenital
Adrenal glands
Editor: Sociedade Brasileira de Endocrinologia e Metabologia
Rights: aberto
Identifier DOI: 10.1590/S0004-27302005000600008
Address: http://dx.doi.org/10.1590/S0004-27302005000600008
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302005000600008
Date Issue: 1-Dec-2005
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
S0004-27302005000600008.pdf69.75 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.